A business in context

CLDX research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-09-22 · 0001104659-26-109465 · Items 8.01,9.01

  2. 8-K · Current report

    Report date 2026-08-06 · 0001171843-26-005316 · Items 2.02,9.01

  3. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001104659-26-091984

  4. 8-K · Current report

    Report date 2026-07-10 · 0001104659-26-083880 · Items 5.02,9.01

  5. 4 · Ownership change

    Report date 2026-06-25 · 0001960596-26-000004

  6. 4 · Ownership change

    Report date 2026-06-25 · 0001838114-26-000002

  7. 4 · Ownership change

    Report date 2026-06-25 · 0001820278-26-000008

  8. 4 · Ownership change

    Report date 2026-06-25 · 0001718112-26-000002

  9. 4 · Ownership change

    Report date 2026-06-25 · 0001709113-26-000002

  10. 4 · Ownership change

    Report date 2026-06-25 · 0001709024-26-000004

  11. 4 · Ownership change

    Report date 2026-06-25 · 0001707797-26-000012

  12. 4 · Ownership change

    Report date 2026-06-25 · 0001681854-26-000002

  13. 8-K · Current report

    Report date 2026-06-25 · 0001104659-26-078023 · Items 5.02,5.07,9.01

  14. 8-K · Current report

    Report date 2026-05-07 · 0001171843-26-003153 · Items 2.02,9.01

  15. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001104659-26-057113

  16. DEF 14A · Proxy statement

    Report date 2026-06-25 · 0001104659-26-050884

  17. 8-K · Current report

    Report date 2026-04-01 · 0001104659-26-038882 · Items 1.01,8.01,9.01

  18. 8-K · Current report

    Report date 2026-02-25 · 0001171843-26-001098 · Items 2.02,9.01

  19. 10-K · Annual report

    Report date 2025-12-31 · 0001104659-26-019652

  20. 8-K · Current report

    Report date 2025-11-10 · 0001171843-25-007179 · Items 2.02,9.01

  21. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001104659-25-109137

  22. 8-K · Current report

    Report date 2025-08-19 · 0001104659-25-080248 · Items 8.01,9.01

  23. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001410578-25-001610

  24. 8-K · Current report

    Report date 2025-08-07 · 0001171843-25-005181 · Items 2.02,9.01

  25. 8-K · Current report

    Report date 2025-06-05 · 0001104659-25-057066 · Items 5.02,5.07,9.01

  26. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001410578-25-001111

  27. 8-K · Current report

    Report date 2025-05-08 · 0001171843-25-002980 · Items 2.02,9.01

  28. DEF 14A · Proxy statement

    Report date 2025-06-05 · 0001104659-25-036562

  29. 10-K · Annual report

    Report date 2024-12-31 · 0001410578-25-000216

  30. 8-K · Current report

    Report date 2025-02-27 · 0001171843-25-001126 · Items 2.02,9.01

  31. SC 13G/A · Ownership disclosure

    0001580642-24-006951

  32. SC 13G/A · Ownership disclosure

    0000902664-24-006640

  33. SC 13G/A · Ownership disclosure

    0000902664-24-006486

  34. SC 13G/A · Ownership disclosure

    0001172661-24-004709

  35. SC 13G/A · Ownership disclosure

    0000315066-24-002724

  36. SC 13G/A · Ownership disclosure

    0000902219-24-000467

  37. 10-Q · Quarterly report

    Report date 2024-09-30 · 0001410578-24-001766

  38. 8-K · Current report

    Report date 2024-11-06 · 0001171843-24-006056 · Items 2.02,9.01

  39. 10-Q · Quarterly report

    Report date 2024-06-30 · 0001410578-24-001219

  40. 8-K · Current report

    Report date 2024-08-08 · 0001171843-24-004603 · Items 2.02,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 0 transaction rows0AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

0 matching transaction rows.

No matching transaction rows in the covered quarter. This does not establish that no insider transactions occurred.

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0000744218Celldex Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • AVANT IMMUNOTHERAPEUTICS INC · former SEC name · 1998-09-01 to 2008-09-29
  • T CELL SCIENCES INC · former SEC name · 1995-11-14 to 1998-08-21

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$7.02M$7.54M
2023-12-31$6.88M$7.61M
2022-12-31$2.36M$2.71M
2021-12-31$4.65M$5.78M
2020-12-31$7.42M$9.66M
2019-12-31$3.57M$4.71M
2018-12-31$9.54M$12.80M
2017-12-31$12.74M$17.52M

Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

Explore the CPI history ↗